Reyataz Capsule, Gelatin Coated
Product Images NDC 0003-3622

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 27 technical images submitted to the FDA as part of the official labeling for Reyataz (NDC 0003-3622). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by E.r. Squibb & Sons, L.l.c., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Reyataz Chemical Structure (Image 01)

FDA Label Image

Reyataz 150 mg Bottle Label (Reyataz 150mg Label)

Reyataz 150 mg Bottle Label (Reyataz 150mg Label)
This is a description of a medication called "REYATAZ®" in capsule form with a strength of 150 mg. The medication comes in a package of 60 capsules with a specific instruction for pharmacists to not cover up the alert box with a pharmacy label. The text also mentions the importance of finding out which medicines should not be taken with REYATAZ®. There is also information regarding the storage temperature of the medicine, which should be kept between 15°C to 25°C. The text does not provide any more details about the medication, its indications or side effects.*
FDA Label Image

Reyataz 200 mg Bottle Label (Reyataz 200mg Label)

FDA Label Image

Reyataz 300 mg Bottle Label (Reyataz 300mg Label)

Reyataz 300 mg Bottle Label (Reyataz 300mg Label)
REYATAZ® (atazanavir) is a capsule medication with a strength of 300 mg. The packaging contains an ALERT label with a warning about medications that should not be taken with this medication. The medication should be kept out of reach of children and stored at room temperature between 15-30°C (59-86°F). The rest of the text is not available due to errors.*
FDA Label Image

Reyataz 50 mg Packet (Reyataz 50mg Packet)

Reyataz 50 mg Packet (Reyataz 50mg Packet)
EYATAZ is an oral powder medication containing atazanavir and is intended for patients who weigh at least 5 kg and are at least 3 months old. Each packet contains 50mg of atazanavir sulfate in 1.5g of powder. This medication contains phenylalanine and should be kept out of the reach of children. Please refer to instructions for use.*
FDA Label Image

Reyataz Figure A (Reyataz Fig A)

FDA Label Image

Reyataz Figure B (Reyataz Fig B)

FDA Label Image

Reyataz Figure C (Reyataz Fig C)

FDA Label Image

Reyataz Figure D (Reyataz Fig D)

FDA Label Image

Reyataz Figure E (Reyataz Fig E)

FDA Label Image

Reyataz Figure F (Reyataz Fig F)

Reyataz Figure F (Reyataz Fig F)
This text suggests that there is a medicine cup with a capacity of 30 milliliters.*
FDA Label Image

Reyataz Figure G (Reyataz Fig G)

FDA Label Image

Reyataz Figure H (Reyataz Fig H)

FDA Label Image

Reyataz Figure I (Reyataz Fig I)

FDA Label Image

Reyataz Figure J (Reyataz Fig J)

FDA Label Image

Reyataz Figure K (Reyataz Fig K)

FDA Label Image

Reyataz Figure L (Reyataz Fig L)

FDA Label Image

Reyataz Figure M (Reyataz Fig M)

FDA Label Image

Reyataz Figure N (Reyataz Fig N)

FDA Label Image

Reyataz Figure O (Reyataz Fig O)

FDA Label Image

Reyataz Figure P (Reyataz Fig P)

FDA Label Image

Reyataz Figure Q (Reyataz Fig Q)

FDA Label Image

Reyataz Figure R (Reyataz Fig R)

FDA Label Image

Reyataz Figure S (Reyataz Fig S)

FDA Label Image

Reyataz Figure T (Reyataz Fig T)

FDA Label Image

Reyataz Figure U (Reyataz Fig U)

FDA Label Image

Reyataz Fig 1 (Reyataz Figure1)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.